TY  - JOUR
A1  - Lu, Yong-Ping
A1  - Lung, Xu-Jing
A1  - Xiao, Xiao-Min
A1  - Huang, Si-Min
A1  - Liu, Zhi-Wei
A1  - Li, Jian
A1  - Hocher, Berthold
A1  - Chen, You-Peng
T1  - Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis
JF  - Clinical laboratory : the peer reviewed journal for clinical laboratories and laboratories related to blood transfusion
N2  - Beckground: Evaluate the efficacy and safety of telbivudine during the 2nd and 3rd trimester of pregnancy in intrauterine transmission of hepatitis B virus (HBV). Based on the principle of Cochrane systematic reviews, a database was constructed from Medline, EMBASE, Cochrane Library, the US National Science Digital Library (NSDL), the China Biological Medicine Database (CBM-disc), and contact with Chinese experts in the field from November 2006 to February 2013.
 Results: Either the Mantel-Haenszel or Inverse Variance fixed-effects model or Mantel-Haenszel or Inverse Variance random-effects model was applied for all analyses indicated by odds ratio (OR) and 95% confidence interval (CI). The meta-analysis based on new onset of HBsAg seropositivity of infants at 6 - 12 months postpartum revealed that the control group had an intrauterine transmission rate of 8.25 - 42.31%. This rate was reduced to 0 - 14.29% in the telbivudine treatment group (OR 0.09, 95% CI 0.04 - 0.22, including seven trials, p < 0.001). The rates of intrauterine transmission based on new onset of HBV DNA seropositivity of infants at 6 - 12 months postpartum were 8.25 - 19.23% in the control group and 0 - 3.57% in the treatment group (OR 0.07, 95% CI 0.02 - 0.22, p < 0.001, including only five trials, since two trials had no data on HBV DNA in infants). With the exception of CK elevations, adverse effect frequencies were similar in both groups.
 Conclusions: Telbivudine is an effective and safe drug for preventing intrauterine transmission of HBV.
KW  - telbivudine
KW  - meta-analysis
KW  - intrauterine
KW  - transmission of hepatitis B virus (HBV)
KW  - clinical studies
KW  - safety efficacy
Y1  - 2014
U6  - https://doi.org/10.7754/Clin.Lab.2013.130408
SN  - 1433-6510
VL  - 60
IS  - 4
SP  - 571
EP  - 586
PB  - Clin Lab Publ., Verl. Klinisches Labor
CY  - Heidelberg
ER  -